Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

• Published in: The Prostate Vol. 76; no. 14; pp. 1257 - 1270
• Main Authors: Junghans, Richard P., Ma, Qiangzhong, Rathore, Ritesh, Gomes, Erica M., Bais, Anthony J., Lo, Agnes S.Y., Abedi, Mehrdad, Davies, Robin A., Cabral, Howard J., Al-Homsi, A. Samer, Cohen, Stephen I.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.10.2016; Wiley Subscription Services, Inc
• Subjects: Aged; Antigens; Antigens, Surface - blood; CAR-T cells; Cytokines; designer T cells; Drug dosages; gene therapy; Glutamate Carboxypeptidase II - antagonists & inhibitors; Glutamate Carboxypeptidase II - blood; Humans; immunotherapy; Interleukin-2 - administration & dosage; Lymphocytes; Male; Middle Aged; Prostate cancer; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - therapy; PSA delay; Receptors, Antigen, T-Cell - administration & dosage; T-Lymphocytes - transplantation; Transplantation, Autologous - methods; Treatment Outcome; Tumors; gene therapy; designer T cells; PSA delay; CAR-T cells; immunotherapy

BACKGROUND Chimeric antigen receptor (CAR)‐modified “designer” T cells (dTc, CAR‐T) against PSMA selectively target antigen‐expressing cells in vitro and eliminate tumors in vivo. Interleukin 2 (IL2), widely used in adoptive therapies, was proven essential in animal models for dTc to eradicate estab...